Skip to main content

Advertisement

Table 2 P-RFA vs. PEI: Results of meta-analysis

From: Meta-analysis of percutaneous radiofrequency ablation versus ethanol injection in hepatocellular carcinoma

Variables No. of studies furnishing data Results RR/WMD (95% CI) P-value I2
   RFA PEI   
Baseline characteristics:      
Child-Pugh grade of liver dysfunction A B 624,26–30 624,26–30 71% 24% 70% 26% 1.05 (0.97, 1.13), 0.44 0.92 (0.74, 1.15), 0.43 0% 0%
Tumour size, cm (mean ± SEM) 426–28,30 2.62 ± 0.33 2.47 ± 0.35 0.13 (0.01, 0.25),0.03 0%
Single nodule 624,26–30 59% 55% 1.04 (0.94, 1.50), 0.44 17%
Follow-up duration, months (mean ± SEM) 326–28 25 ± 6.2 23.6 ± 5.6 0.97 (-1.32, 3.3), 0.4 0%
Efficacy:      
Survival 1 year 2 years 3 years 4 years 526–30 526–30 427–30 229,30 96% 86% 73% 62% 91% 75% 58% 51% 1.04 (1.007, 1.08), 0.02 1.13 (1.06, 1.20), <0.001 1.28 (1.12, 1.45), <0.001 1.24 (1.05,1.48), <0.001 0% 0% 12.6% 0%
Local recurrence 426–29 7% 22% 0.37 (0.23, 0.59), 0.000 0%
Disease-free survival 1 year 2 years 3 years 326–28 326–28 227,28 80% 61% 40% 70% 42% 19% 1.13 (1, 1.28), 0.04 1.31 (1.06, 1.61), 0.013 2.1 (1.35, 3.23), 0.001 0% 0% 0%
Tumour complete response 424,26–28 93.5% 84.5% 1.10 (1.04, 1.17), 0.01 0%
Remote intra-hepatic recurrence 526–30 43% 45% 0.97 (0.82, 1.11), 0.56 0%
Safety:      
Total complications 624,26–30 19.2% 10.5% 2.55 (1.8, 3.65), <0.001 0%
Major complications 424,28–30 4.1% 2.7% 1.85 (0.68, 5.01); 0.22 0%
  1. RR: Relative risk. WMD: Weighted mean difference. All based on random effects meta-analysis.